Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio Breast Cancer Symposium

SEATTLE, Nov. 15, 2016 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that two abstracts on the Company’s lead product candidate tucatinib (also known as ONT-380) will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) to be held December 6-10 in San Antonio, TX.

The Phase 1b “Triplet” poster presentation will include more mature progression-free survival (PFS) and safety data not included in the abstract posted on the SABCS website, which was as of May 2016.

Details of Poster Presentations:

A Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine (C) and Trastuzumab (T) in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (MBC) (HER2CLIMB)
First Author:  Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session:  OT1-02-09, Ongoing Trials – Chemotherapy
Date/Time:  Wednesday, December 7, 2016; 5:00 p.m.–7:00 p.m. CST

Efficacy Results of a Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in HER2+ Metastatic Breast Cancer (MBC), Including Patients (pts) with Brain Metastases (mets)
First Author:  Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN
Poster/Session:  P4-21-01, Treatment: HER2-Targeted Therapy
Date/Time:  Friday, December 9, 2016; 7:30 a.m.–9:00 a.m. CST

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information and to sign up for email alerts or RSS feeds, please visit www.cascadianrx.com.

Contacts:

Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]

Media:
Brad Miles
BMC Communications
917-570-7340
[email protected]